Vascular rheumatology: Atherosclerosis and cardiovascular disease in arthritis

Research output: Contribution to journalArticle

Abstract

Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis to increased vascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Inflammatory risk factors leading to atherosclerosis include pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) or interleukin 6 (IL-6) in RA and SpA. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have been published.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalReumatologia
Volume26
Issue number1
Publication statusPublished - 2012

Fingerprint

Rheumatology
Arthritis
Blood Vessels
Atherosclerosis
Cardiovascular Diseases
Spondylarthropathies
Carotid Intima-Media Thickness
Rheumatic Diseases
Vasodilation
Rheumatoid Arthritis
Cytokines
Pulse Wave Analysis
Vascular Stiffness
Antirheumatic Agents
Brachial Artery
Immunosuppressive Agents
Vascular Diseases
Chemokines
Autoantibodies
Interleukin-6

Keywords

  • Arthritis
  • Atherosclerosis
  • Biologies
  • Cardiovascular disease
  • Endothelial dysfunction

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Vascular rheumatology : Atherosclerosis and cardiovascular disease in arthritis. / Szekanecz, Z.

In: Reumatologia, Vol. 26, No. 1, 2012, p. 27-34.

Research output: Contribution to journalArticle

@article{065b8580d45049168223b1591a0cfec6,
title = "Vascular rheumatology: Atherosclerosis and cardiovascular disease in arthritis",
abstract = "Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis to increased vascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Inflammatory risk factors leading to atherosclerosis include pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) or interleukin 6 (IL-6) in RA and SpA. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have been published.",
keywords = "Arthritis, Atherosclerosis, Biologies, Cardiovascular disease, Endothelial dysfunction",
author = "Z. Szekanecz",
year = "2012",
language = "English",
volume = "26",
pages = "27--34",
journal = "Reumatologia",
issn = "0034-6233",
publisher = "Termedia Publishing House Ltd.",
number = "1",

}

TY - JOUR

T1 - Vascular rheumatology

T2 - Atherosclerosis and cardiovascular disease in arthritis

AU - Szekanecz, Z.

PY - 2012

Y1 - 2012

N2 - Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis to increased vascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Inflammatory risk factors leading to atherosclerosis include pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) or interleukin 6 (IL-6) in RA and SpA. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have been published.

AB - Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis to increased vascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. Accelerated atherosclerosis and increased cardio- and cerebrovascular morbidity and mortality have been associated with rheumatoid arthritis (RA) and spondyloarthropathies (SpA). Inflammatory risk factors leading to atherosclerosis include pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) or interleukin 6 (IL-6) in RA and SpA. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have been published.

KW - Arthritis

KW - Atherosclerosis

KW - Biologies

KW - Cardiovascular disease

KW - Endothelial dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84861487806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861487806&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84861487806

VL - 26

SP - 27

EP - 34

JO - Reumatologia

JF - Reumatologia

SN - 0034-6233

IS - 1

ER -